| EN

Sanbexin™:edaravone and dexborneol concentrated solution for injection

Sanbexin™:edaravone and dexborneol concentrated solution for injection

Indications:

used to improve the neurological symptoms and dysfunction of activities of daily living caused by acute cerebral infarction.

With its dual mechanism of action, edaravone and dexborneol concentrated solution for injection scavenges free radicals, inhibits inflammatory response and improves the permeability in blood-brain barrier, minimizing brain injury or impairment caused by acute ischemic stroke.

Compared with other pharmaceuticals for treatment of stroke, edaravone and dexborneol concentrated solution for injection has a significantly higher efficacy than edaravone monotherapy.

A randomized, double-blind, positive controlled, head to head comparison phase III study in approximately 1,200 acute ischemic stroke patients has shown that, compared to edaravone monotherapy, edaravone and dexborneol concentrated solution for injection has significantly higher efficacy with similar safety profile, extending the therapeutic time window from 24 hours to 48 hours.